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Abstract
Few randomized controlled trials (RCTs) with large numbers 
of patients have been conducted to date in patients with biliary 
tract cancer, and standard chemotherapy has not been estab-
lished yet. In this article we review previous studies and clini-
cal trials regarding chemotherapy for unresectable biliary 
tract cancer, and we present guidelines for the appropriate use 
of chemotherapy in patients with biliary tract cancer. Accord-
ing to an RCT comparing chemotherapy and best supportive 
care for these patients, survival was signiﬁ  cantly longer and 
quality of life was signiﬁ  cantly better in the chemotherapy 
group than in the control group. Thus, chemotherapy for 
patients with biliary tract cancer seems to be a signiﬁ  cant 
treatment of choice. However, chemotherapy for patients with 
biliary tract cancer should be indicated for those with un-
resectable, locally advanced disease or distant metastasis, or 
for those with recurrence after resection. That is why making 
the diagnosis of unresectable disease should be done with 
greatest care. As a rule, pathological diagnosis, including cytol-
ogy or histopathological diagnosis, is preferable. Chemother-
apy is recommended in patients with a good general condition, 
because in patients with general deterioration, such as those 
with a performance status of 2 or 3 or those with insufﬁ  cient 
biliary decompression, the beneﬁ  t of chemotherapy is limited. 
As chemotherapy for unresectable biliary tract cancer, the use 
of gemcitabine or tegafur/gimeracil/oteracil potassium is 
recommended. As postoperative adjuvant chemotherapy, no 
effective adjuvant therapy has been established at the present 
time. It is recommended that further clinical trials, especially 
large multi-institutional RCTs (phase III studies) using novel 
agents such as gemcitabine should be performed as soon as 
possible in order to establish a standard treatment.
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Introduction
Chemotherapy in patients with biliary tract cancer is 
indicated in those with unresectable advanced cancer 
and patients with recurrence after resection. However, 
no standard chemotherapy for biliary tract cancer has 
yet been established, because few randomized con-
trolled trials (RCTs) with large numbers of patients 
have been conducted to date. There are a number of 
studies regarding chemotherapy for biliary tract cancer, 
but many of these studies were prospective clinical trials 
with small numbers of patients, corresponding to phase 
II studies, or retrospective studies, so high-level evi-
dence in this area is limited. According to the “Classiﬁ  -
cation of Biliary Tract Carcinoma”, bile duct cancer, 
gallbladder cancer, and ampullary cancer are classiﬁ  ed 
as biliary tract cancer, and there are some clinical trials 
and articles in which treatment results that include those 
in intrahepatic bile duct cancer are also reported. If 
clinical trials are conducted for individual diseases sepa-
rately, difﬁ  culties are encountered in view of efﬁ  ciency 
and implementation, and so far, clinical trials of chemo-
therapy have been carried out only for biliary tract 
cancer in general. However, because treatment policy, 
sensitivity to chemotherapy, and prognosis differ widely 
from disease to disease, the treatment results of chemo-
therapy in biliary tract cancer should be evaluated on 
the basis of a full understanding of individual back-
ground factors.
In the present guidelines, chemotherapy for unresect-
able biliary tract cancer and postoperative adjuvant 
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chemotherapy has been described based on results from 
clinical trials and retrospective studies performed up to 
now. In order that effective chemotherapy for biliary 
tract cancer may be developed, active implementation 
of clinical trials is recommended. Also, large multi-
institutional RCTs (phase III) should be conducted to 
establish standard treatment as soon as possible.
The only procedure in biliary cancer that confers a 
cure is curative surgical resection, so a diagnosis of 
incurability should be made with caution. Lest the 
cancer be benign, surgical treatment should be admin-
istered as a rule only after pathological diagnosis (such 
as cytological and histological diagnoses) has been 
made. The chemotherapy described in the these Guide-
lines is concerned with adenocarcinoma, which has the 
highest frequency of occurrence, so pertinent literature 
should be referred to in selecting treatment methods for 
other speciﬁ  c pathological types of cancer. In these 
Guidelines, clinical questions (CQs) are posed, with 
responses in the form of recommendations (grades 
of the recommendations are deﬁ  ned in Table 1
1). 
Also, levels of evidence are given (in parentheses) for 
ﬁ  ndings in reference citations (see deﬁ  nitions of levels 
in Table 2
1).
Chemotherapy is recommended in patients with good 
general physical condition (recommendation C1).
To assess the efﬁ  cacy of chemotherapy in achieving pro-
longed survival in biliary tract cancer, veriﬁ  cation is 
necessary by comparing it with supportive treatment 
CQ 1 Does chemotherapy have any beneﬁ  ts in 
patients with unresectable biliary tract cancer?
alone. To date, only two small RCTs (level II) have been 
published.
2,3
An RCT on chemotherapy and supportive treatment 
was conducted in patients with unresectable pancreas 
cancer and biliary tract cancer.
2 In this study, ﬂ  uoroura-
cil (5-FU) + leucovorin or 5-FU + leucovorin + etopo-
side were used for chemotherapy. For all the patients, 
signiﬁ  cantly prolonged survival was observed in the 
group who received chemotherapy (median survival 
time [MST], 6.0 months) compared with the group who 
received supportive treatment alone (MST, 2.5 months). 
However, due to the small number of patients with 
biliary tract cancer (37 patients), no signiﬁ  cant differ-
ence was established between the groups (chemother-
apy group MST, 6.5 months; supportive treatment group, 
2.5 months; P = 0.1). The rate of improvement in quality 
of life (QOL) was also examined in this trial, and a 
signiﬁ  cant difference was found in the chemotherapy 
group compared with the supportive treatment group 
(P < 0.01); an improvement of 36% was observed in the 
chemotherapy group (pancreas cancer, 38%; biliary 
tract cancer, 33%) and an improvement of 10% (pan-
creas cancer, 13%; biliary tract cancer, 5%) was shown 
in the supportive treatment group.
The other small RCT
3 was conducted in Japan, com-
paring chemotherapy with 5-FU + doxorubicin + mito-
mycin C (FAM) and palliative treatment, such as bypass, 
in patients with unresectable pancreatic cancer, gallblad-
der cancer, and bile duct cancer. No signiﬁ  cant improve-
ment in prognosis was achieved in either group, but in the 
patients with gallbladder cancer, a good prognosis was 
achieved in the chemotherapy group (level II).
A retrospective analysis comparing chemotherapy 
and supportive treatment in patients with gallbladder 
cancer was carried out. No survival beneﬁ  t owing to 
chemotherapy was observed in patients with a perfor-
mance status of 2, while prolonged survival in the 
chemotherapy group was observed in patients with a 
performance status of 0 or 1
4 (level IV).
Concerning the efﬁ  cacy of chemotherapy for unre-
sectable biliary tract cancer, no evidence based on an 
RCT with a large number of patients is available, but 
there are reports demonstrating the efﬁ  cacy of chemo-
therapy in achieving improved QOL and prolonged 
survival. Thus, the strength of the recommendation for 
chemotherapy was determined as C1.
2–4
Table 1.  Strength of recommendations
1
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is a 
lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
1
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
patient’s dataJ. Furuse et al.: Chemotherapy for biliary cancer  57
Table 3.  Systemic chemotherapy with single agents for biliary tract cancer
Agent n
Response 
rate MST (months) Study design
Evidence 
level Author Year Reference
Fluorouracil
5-FU 18 0% — RCT Level II Takada 1994 19
5-FU/LV/HU 30 30% 8.0 Cohort study Level III Gebbia 1996 22
5-FU/α-IFN 32 34% 12.0 Cohort study Level III Patt 1996 23
5-FU/LV 18 33% 7.0 Cohort study Level III Chen 1998 24
5-FU/LV 28 32% 6.0 Cohort study Level III Choi 2000 25
5-FU/FA 30 7% 14.8 Cohort study Level III Malik 2003 26
UFT/LV 13 0% 6.5 Cohort study Level III Mani 1999 5
UFT/LV 16 0% 4.5 Cohort study Level III Chen 2003 6
Capecitabine 26 19% CC, 8.1; GB, 9.9 Cohort study Level III Patt 2004 27
S-1 19 21% 8.3 Cohort study Level III Ueno 2004 28
UFT 19 5% 8.8 Cohort study Level III Ikeda 2005 7
S-1 40 30% 9.4 Cohort study Level III Furuse in press 9
Taxanes
Paclitaxel 15 0% — Cohort study Level III Jones 1996 29
Docetaxel 16 0% — Cohort study Level III Pazdur 1999 30
Docetaxel 24 20% 8.0 Cohort study Level III Papakostas 2001 31
Gemcitabine
Gemcitabine (800 mg/m
2)3 0 30% 14.0 Cohort study Level III Tsavaris 2004 32
Gemcitabine (1000 mg/m
2)2 5 36% 7.0 Cohort study Level III Gallardo 2001 33
Gemcitabine (1000 mg/m
2)2 4 13% 7.2 Cohort study Level III Lin 2003 34
Gemcitabine (1000 mg/m
2)4 0 18% 7.6 Cohort study Level III Okusaka 2006 8
Gemcitabine (1200 mg/m
2)1 9 16% 6.5 Cohort study Level III Raderer 1999 35
Gemcitabine (1500 mg/m
2)1 50 % 4.6 Cohort study Level III Eng 2004 36
Gemcitabine (2200 mg/m
2)3 2 22% 11.5 Cohort study Level III Penz 2001 27
Others
Mitomycin C 30 10% 4.5 Cohort study Level III Taal 1993 38
Cisplatin 13 8% 5.5 Cohort study Level III Okada 1994 39
Irinotecan 36 8% 6.1 Cohort study Level III Alberts 2002 40
Erlotinib 42 8% 7.5 Cohort study Level III Philip 2006 14
MST, median survival time; 5-FU, 5-ﬂ  uorouracil; IFN, interferon; LV, levofolinic acid (leucovorin); FA, folinic acid; HU, hydroxyurea; CC, 
cholangiocarcinoma; GB gallbladder
CQ 2  What is a recommended chemotherapy 
regimen?
As chemotherapy for unresectable advanced biliary 
tract carcinoma, gemcitabine or tegafur/gimeracil/
oteracil potassium is recommended (recommendation 
C1).
The use of chemotherapy for biliary tract cancer 
should be limited to patients with unresectable, locally 
advanced disease and distant metastasis, or those with 
recurrence after resection. Chemotherapy is recom-
mended in patients with a good general condition. 
However, in patients with general deterioration (perfor-
mance status of 2 or 3) or those with insufﬁ  cient biliary 
decompression, the beneﬁ  t of chemotherapy is small, so 
care should be taken in considering its indications. In 
these patients, palliative treatment targeting the main-
tenance of QOL should be administered, including pain 
control and the placement of stents in the bile duct.
Table 3 shows the results of systemic chemotherapy 
with a single agent for biliary tract cancer. The single 
use of ﬂ  uoropyrimidines such as 5-FU, or a combination 
of 5-FU with interferon, leucovorin, or hydroxyurea 
as biochemical modulators, was often used for advanced 
biliary tract cancer. A favorable response rate of 
more than 30% has been reported with the combined 
use of a single agent with these modulators, but no 
difference was observed in MST, which ranged from 
7 to 12 months, in studies in patients undergoing che-
motherapy for unresectable biliary tract cancer, com-
pared with patients who received best supportive 
care (level III). In Japan, uracil–tegafur (UFT) is 
approved by the Ministry of Health, Labor, and Welfare 
for biliary tract cancer. However, regimens of UFT 
alone or UFT plus leucovorin were reported to have 
objective responses of 5% and 0%, respectively, and 
more than 60% patients were evaluated as having pro-
gressive disease in these regimen. Therefore, UFT 
should not be used alone for biliary tract cancer (level 
III).58  J. Furuse et al.: Chemotherapy for biliary cancer
A clinical trial of tegafur/ gimeracil/oteracil potas-
sium (S-1), which is an oral anticancer drug that consists 
of tegafur (FT) as a prodrug of 5-FU, 5-chloro-2, 4-
dihydroxypyridine (CDHP), and potassium oxonate 
(Oxo), was conducted in Japan. S-1 was orally adminis-
tered at a dose of 80 mg/m
2 per day for 28 days, followed 
by 14 days of rest. In a late phase II trial, a favorable 
result was reported, with a success rate of 35% and MST 
of 9.4 months in 40 patients. Because of this result, insur-
ance coverage for the use of this agent for biliary tract 
cancer was endorsed in August, 2007 (level III).
There are also some reports of the use of mitomycin 
C, cisplatin, taxanes, and irinotecan (CPT-11) (Table 3), 
but no satisfactory result has been achieved (level III).
For biliary tract cancer, there is a limitation in treat-
ment effects brought about by chemotherapy with the 
use of a single agent, so many modalities of combination 
chemotherapy have been carried out (Table 4). Com-
pared with single-agent chemotherapy, the response 
rate of combination chemotherapy is generally high and 
the survival period is also inclined to be long. Although 
a regimen of a combination of 5-FU, anthracycline, and 
platinum has often been employed, no standard regimen 
has been established. An attempt at a regimen focusing 
Table 4.  Combination chemotherapy for biliary tract cancer
Regimen n
Response 
rate
MST 
(months) Study design
Evidence 
level Author  Year Reference
5-FU-based
5-FU/ADM/MMC (FAM) 14 29% 8.5  Cohort study Level III Harvey 1984 41
EPI/MTX/5-FU/LV 17 0% 9.0  Cohort study Level III Kajanti 1994 42
5-FU/LV/MMC 20 25% 9.5  Cohort study Level III Raderer 1999 35
MMC/5-FU/LV 19 26% 6.0  Cohort study Level III Chen 2001 43
Platinum-based
EPI/CDDP/5-FU (ECF) 20 40% 11.0  Cohort study Level III Ellis  1995 44
CDDP/EPI/5-FU (CEF) 37 19% 5.9  Cohort study Level III Morizane  2003 45
5-FU/CDDP  25 24% 10.0  Cohort study Level III Ducreux 1998 46
5-FU/CDDP/LV 29 34% 9.5  Cohort study Level III Taieb 2002 47
Capecitabine/CDDP 42 21% 9.1  Cohort study Level III Kim TW 2003 48
CDDP/IFN/DXR/5-FU (PIAF) 38 21% 14.0  Cohort study Level III Patt 2001 49
EPI/CDDP/UFT/LV 40 23% 7.9  Cohort study Level III Park KH  2005 50
EPI/CDDP/capecitabine 43 40% 8.0  Cohort study Level III Park SH 2006 51
5-FU/LV/Carboplatin 14 21% 5.0  Cohort study Level III Sanz-Altamira 1998 52
5-FU/LV/Oxaliplatin (FOLFOX) 16 19% 9.5  Cohort study Level III Nehls 2002 53
Gemcitabine-based
Gemcitabine/Docetaxel 43 9% 11.0  Cohort study Level III Kuhn 2002 54
Gemcitabine/5-FU 27 33% 5.3  Cohort study Level III Knox 2004 55
Gemcitabine/5-FU/LV 42 12% 4.7  Cohort study Level III Hsu 2004 56
Gemcitabine/5-FU/LV 42 12% 9.7  Cohort study Level III Alberts  2005 57
Gemcitabine/CDDP 30 38% 4.6  Cohort study Level III Doval 2004 10
Gemcitabine/CDDP 40 28% 8.4  Cohort study Level III Thongprasert  2005 11
Gemcitabine/CDDP 29 35% 11.0  Cohort study Level III Kim ST 2006 12
Gemcitabine/CDDP 27 33% 10.0  Cohort study Level III Park BK 2006 13
Gemcitabine/oxaliplatin 33 33% 15.4  Cohort study Level III Andre  2004 58
Gemcitabine/capecitabine 45 31% 14.0  Cohort study Level III Knox 2005 16
Gemcitabine/capecitabine 45 32% 14.0  Cohort study Level III Cho 2005 59 
MST, median survival time; MTX, methotrexate; MMC, Mitomycin C; 5-FU, 5-ﬂ  uorouracil; LV, leucovorin; IFN, interferon
Since 1999, clinical trials have been conducted with 
gemcitabine. Although methods of administration are 
different, relatively good results are reported (Table 3). 
A clinical trial (phase II) was carried out with gem-
citabine alone in Japan.
8 A response rate of 17.5% (95% 
conﬁ  dence intervals [CI], 7.3%–32.8%), and an MST of 
7.6 months was achieved with the standard dosage, 
which was 1000 mg/m
2 as a 30-min intravenous infusion 
weekly, given for 3 consecutive weeks, followed by a 
week of rest, the results being roughly similar to those 
of reports from abroad. Toxicity inducing myelosup-
pression, such as leucopenia, as well as nausea and 
anorexia, was mainly observed, but tolerance was good. 
Based on these results, gemcitabine was approved by 
the Ministry of Health, Labour, and Welfare, in June, 
2006, for use in biliary tract cancer (level III).
Side memo
In Japan, none of the above modulators are 
approved by the Ministry of Health, Labour, and Welfare 
for use as chemotherapeutic drugs in biliary tract cancer.J. Furuse et al.: Chemotherapy for biliary cancer  59
on the use of gemcitabine is currently being made and 
a favorable result has been achieved, with the response 
rate being 21%–48% and MST, 4.6–11.0 months in 
patients treated with gemcitabine + cisplatin
10–13 (level 
III). Currently, a large controlled trial comparing gem-
citabine alone and gemcitabine + cisplatin (CDDP) is 
being conducted chieﬂ  y by an English group and it is 
drawing attention. Also, therapeutic drugs targeting 
molecular biological characteristics (molecular target-
ing therapy) are now under development. In view of a 
report suggesting the strong expression of epithelial 
growth factor receptor (EGFR) in biliary tract cancer, 
a phase II trial using erlotinib, which is an EGFR-
inhibiting drug, is being carried out.
14
In biliary tract cancer, treatment results differ widely 
depending upon the site of the cancer. In clinical trials, 
patients’ backgrounds, particularly the proportions of 
those with gallbladder cancer, bile duct cancer, and 
ampullary cancer, have a big impact on treatment 
results, such as the survival period.
7,15,16 In a phase II 
study of gemcitabine +  capecitabine, the MST in 
patients with gallbladder cancer was 6.6 months and 
the MST in patients with bile duct cancer was 19 
months; thus, this difference in MST was assumed to 
be due to a biological difference.
16 In overseas clinical 
trials of chemotherapy for biliary tract cancer, intrahe-
patic cholangiocarcinoma is often included. In Japan, 
Table 5.  Randomized clinical trials for unresectable biliary tract cancer
n
Response 
rate
MST 
(months) 
GB/BD P value
Study 
design 
Evidence 
level Author (year) Reference
1)  Oral 5-FU 30 10% 4.9/6.1 NS RCT Level II Falkson (1984) 60
2) Oral  5-FU + Stz 26 7.7% 3.3/2.8
3) Oral  5-FU + MeCCNU 31 9.7% 2.3/1.9
1) Modiﬁ  ed FAM 35 (18)
a 4% 6.2
b NS RCT Level II Takada (1994) 19
2) 5-FU 36  (18)
a 0% 6.0
b
1) 5-FU  + LV or FELV 47 (18)
a 11% 6.5 (6.5)
b 0.1 RCT Level II Glimelius (1996) 2
2) BSC 43  (19)
a — 2.5 (2.5)
b
1) Modiﬁ  ed FAM 14 — 5.2/4.1 NS RCT Level II Takada (1998) 3
2) Palliative  surgery 17 — 2.4/7.7
1) MMC  + gemcitabine 25 20% 6.7 — RCT Level II Kornek (2004) 61
2) MMC  + capecitabine 26 31% 9.3
1)  5-FU 29 — 5.0 — RCT Level II Ducreux (2005) 62
2) 5-FU  + FA + cisplatin 29 — 8.0
1) ECF  27 — 9.0 0.72 RCT Level II Rao (2005) 63
2) FELV 27 — 12.0
MST, median survival time; GB, gallbladder; BD, bile duct; Stz, streptozotocin; MeCCNU, methyl-CCNU; LV, levofolinic acid (lecovorin); 
BSC, best supportive care; MMC, mitomycin C; FA, folinic acid; FAM, 5-FU + adriamycin + MMC; FELV, 5-FU + etoposide + leucovorin; ECF, 
epirubicin + cisplatin + 5-FU
a The total number of patients in the study, including those with pancreatic cancer; numbers in parentheses, numbers of patients with biliary tract 
cancer
b The median overall survival time in all patients in the study, including those with pancreatic cancer; numbers in parentheses, median overall 
survival times in patients with biliary tract cancer
however, intrahepatic cholangiocarcinoma was often 
excluded from clinical trials of biliary tract cancer, 
because this entity is classiﬁ  ed as primary liver cancer 
in the “General rules for the clinical and pathological 
study of primary liver cancer,
17” published by the Liver 
Cancer Study Group of Japan
18  and the “TNM clas-
siﬁ  cation of malignant tumours,” published by the 
International Union Against Cancer. Also, some clinical 
trials include ampullary cancer and some do not. 
Ideally, clinical trials of chemotherapy for biliary tract 
cancer and the assessment of treatment results should 
be carried out independently according to the individ-
ual diseases, but due to the small numbers of patients 
with the individual diseases, making an analysis of dis-
eases independently is difﬁ  cult. Therefore, RCTs with 
large numbers of patients and adequate stratiﬁ  cation 
of all patients concerned should be conducted to evalu-
ate the results of chemotherapy.
The number of RCTs that have been conducted con-
cerning chemotherapy for bile duct cancer is not so 
large. Outlined in Table 5 are RCTs retrieved from a 
literature search. In Japan, comparisons were made by 
Takada et al.
3,19  between FAM and 5-FU alone and 
between FAM and palliative treatment, such as bypass 
operation. No signiﬁ  cant difference in survival was con-
ﬁ  rmed in these RCTs, and a standard chemotherapy has 
not been established yet (level II).60  J. Furuse et al.: Chemotherapy for biliary cancer
of postoperative adjuvant therapy is suggested by such 
trials.
Todoroki summarized the results of clinical trials of 
chemotherapy for gallbladder cancer and veriﬁ  ed that 
postoperative chemotherapy was efﬁ  cacious. Most of 
these clinical trials were conducted using a single arm, 
so no regimen could be selected as a possible candidate 
for postoperative adjuvant therapy.
21 Recently, chemo-
therapy focusing on gemcitabine for unresectable biliary 
tract cancer has been conducted, and regimens with 
good anticancer effects have sometimes been observed. 
However, no large RCTs of postoperative adjuvant 
therapy have been carried out with the use of such regi-
mens. RCTs of postoperative adjuvant therapy, using 
new agents including gemcitabine and S-1, should be 
conducted vigorously. At the present time, no recom-
mendable postoperative adjuvant therapy has been dis-
covered, so clinical trials of various forms of chemotherapy 
are anticipated in the future.
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Table 6.  Randomized clinical trial of adjuvant chemotherapy 
for pancreas and biliary tract cancer
20
n 5-Year survival rate P value
Pancreas
Mitomycin C/5-FU 81 11.5% NS
Surgery alone 77 18.0%
Gallbladder
Mitomycin C/5-FU 69 26.0% 0.037
Surgery alone 43 14.4%
Biliary tract 
Mitomycin C/5-FU 58 26.7% NS
Surgery alone 60 24.1%
Ampulla of Vater
Mitomycin C/5-FU 24 28.1% NS
Surgery alone 24 34.3% No recommendable regimen is available now, but it 
is hoped that adjuvant chemotherapy can be carried 
out as a clinical trial. (recommendation C1).
In gallbladder and bile duct cancers, early recurrence 
often occurs even if these patients have received cura-
tive resection; the prognosis in patients with recurrence 
is extremely poor. Therefore, further development of 
effective measures for preventing recurrence through 
postoperative adjuvant therapy is eagerly anticipated. 
In view of the low incidence of biliary tract cancer in 
Western countries, where a large number of clinical 
studies of postoperative adjuvant therapy have been 
conducted in other types of cancer, few RCTs of post-
operative adjuvant therapy for biliary tract cancer have 
been carried out. On the other hand, in the East Asian 
region (including Japan), the incidence of biliary tract 
cancer is high so RCTs of postoperative adjuvant 
therapy have been carried out in Japan.
From 1986 to 1992, Takada et al. performed an RCT 
in which 508 patients with pancreas cancer and biliary 
tract cancer were assigned to a group in which combina-
tion chemotherapy using 5-FU and mitomycin C (MMC) 
was administered (MF group) and a group for whom 
surgery alone was conducted (control group); the results 
were reported with a postoperative follow-up period of 
5 years.
20 As eligible patients, 158 patients with pan-
creatic cancer, 118 patients with bile duct cancer, 112 
patients with gallbladder cancer, and 48 patients with 
ampullary cancer were chosen. Analysis was done 
independently in the individual diseases, and the 5-year 
survival rate was found to be signiﬁ  cantly better in the 
MF group for gallbladder cancer (Table 6) (level II). 
However, according to a review of the degree of cure 
due to resection, a signiﬁ  cant difference in survival rate 
was found only in patients with noncurative resection. 
On the basis of an intent-to-treat analysis, no signiﬁ  cant 
difference between the MF and the control group was 
observed in patients with gallbladder cancer. MF therapy 
has not yet been established as standard postoperative 
adjuvant therapy in biliary tract cancer, but the efﬁ  cacy 
CQ 3 Does adjuvant chemotherapy after surgery 
have a survival beneﬁ  t?
As chemotherapy for biliary tract cancer at the 
present time, gemcitabine or S-1, which is covered 
by insurance in Japan, is recommended on the basis 
of the results of many phase II trials, including those 
performed in Japan (level III). Evidence-based stan-
dard treatment should be established in the future by 
conducting controlled trials with the use of these 
agents.J. Furuse et al.: Chemotherapy for biliary cancer  61
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